# US 2019/0315887 A1 · Combination of cross-linked hyaluronic acids and method of preparing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315887 A1
- Document ID: US20190315887A1
- Status: Published application
- Kind: A1
- Application number: 16/448,180
- Filed: 2019-06-21
- Published: 2019-10-17
- Earliest claimed: 2016-01-29
- Assignees: Hanmi Pharm. Co., Ltd.
- Applicants: Hanmi Pharm. Co., Ltd.
- Inventors: Sung Chul CHOI; Hyun Il KIM; Ki Young YANG; Hyo Seung PARK; Back Ho LEE
- Web page: https://patentgrep.com/patent/US20190315887A1

## CPC

- C08B 37/0072: {Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates}
- A61K 8/0241: {Containing particulates characterized by their shape and/or structure (see also A61K8/04, A61K8/11, and A61K8/14, further aspects are classified in A61K2800/40 and subcodes)}
- A61K 8/735: {Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 27/20: Polysaccharides
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61Q 19/08: Anti-ageing preparations
- C08J 3/24: Crosslinking, e.g. vulcanising, of macromolecules (mechanical aspects B29C35/00; crosslinking agents C08K)
- C08L 5/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/34: for soft tissue reconstruction
- C08J 2305/08: Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
- C08L 2205/025: containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C08J: WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H (working, e.g. shaping, of plastics B29)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Provided are a combination of cross-linked hyaluronic acids comprising: a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, and a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, and a method for preparing the same.

## Claims

### Claim 1

A combination of cross-linked hyaluronic acids comprising:
a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, and
a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa.

### Claim 2 (depends on 1)

The combination of cross-linked hyaluronic acids of claim 1 having an elasticity of about 100 to about 150 Pa and a viscosity of about 20 to about 60 Pa.

### Claim 3 (depends on 2)

The combination of cross-linked hyaluronic acids of claim 2, wherein the cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa and the cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa are combined in a weight ratio of about 8:2 to about 9:1.

### Claim 4

A combination of cross-linked hyaluronic acids comprising:
a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, and prepared by a method comprising cross-linking hyaluronic acid with an epoxy-based cross-linking agent having at least two epoxy functional groups in an ethanol-containing aqueous alkaline solution; and
a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, and prepared by a method comprising cross-linking the cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa with an epoxy-based cross-linking agent having at least two epoxy functional groups in an aqueous alkaline solution.

### Claim 5 (depends on 4)

The combination of cross-linked hyaluronic acids of claim 4 having an elasticity of about 100 to about 150 Pa and a viscosity of about 20 to about 60 Pa.

### Claim 6 (depends on 5)

The combination of cross-linked hyaluronic acids of claim 5, wherein the cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa and the cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa are combined in a weight ratio of about 8:2 to about 9:1.

### Claim 7 (depends on 5)

The combination of cross-linked hyaluronic acids of claim 5, wherein the combination of cross-linked hyaluronic acids is in the form of particles having an average particle size of about 500 to about 750 μm.

### Claim 8 (depends on 4)

A biocompatible material comprising the combination of cross-linked hyaluronic acids of claim 4.

### Claim 9 (depends on 8)

The biocompatible material of claim 8, wherein the biocompatible material is selected from the group consisting of arthritis treatment implants, wrinkle fillers, cosmetic fillers, and drug carriers.

### Claim 10

A method of preparing a combination of cross-linked hyaluronic acids comprising:
combining (a) a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa with (b) a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa;
wherein the (a) cross-linked hyaluronic acid is prepared by a method comprising cross-linking hyaluronic acid with an epoxy-based cross-linking agent having at least two epoxy functional groups in an ethanol-containing aqueous alkaline solution;
wherein the (b) cross-linked hyaluronic acid is prepared by a method comprising cross-linking the cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa with an epoxy-based cross-linking agent having at least two epoxy functional groups in an aqueous alkaline solution; and
wherein the combining ratio is adjusted to meet a target viscoelasticity of the combination of cross-linked hyaluronic acids to be prepared.

### Claim 11 (depends on 10)

The method of claim 10, wherein the combining ratio of the (a) cross-linked hyaluronic acid to the (b) cross-linked hyaluronic acid is about 9:1 to about 8:2 by weight.

### Claim 12 (depends on 10)

The method of claim 10, wherein the hyaluronic acid is obtained by fermentation with a microorganism.

### Claim 13 (depends on 10)

The method of claim 10, wherein the hyaluronic acid includes hyaluronic acid, a salt of hyaluronic acid, or a mixture thereof.

### Claim 14 (depends on 10)

The method of claim 10, wherein the salt of hyaluronic acid is selected from the group consisting of sodium hyaluronate, potassium hyaluronate, magnesium hyaluronate, zinc hyaluronate, cobalt hyaluronate, tetrabutylammonium hyaluronate, and a combination thereof.

### Claim 15 (depends on 10)

The method of claim 10, wherein the hyaluronic acid comprises sodium hyaluronate having a molecular weight of about 100,000 to about 6,000,000.

### Claim 16 (depends on 10)

The method of claim 10, wherein the epoxy-based cross-linking agent having at least two epoxy functional groups is selected from the group consisting of 1,4-butanediol diglycidyl ether (BDDE), ethylene glycol diglycidyl ether (EGDGE), 1,6-hexanediol diglycidyl ether, propylene glycol diglycidyl ether, polypropylene glycol diglycidyl ether, polytetramethylene glycol diglycidyl ether, neopentyl glycol diglycidyl ether, polyglycerol polyglycidyl ether, diglycerol polyglycidyl ether, glycerol polyglycidyl ether, trimethylpropane polyglycidyl ether, 1,2-(bis(2,3-epoxypropoxy)ethylene, pentaerythritol polyglycidyl ether, sorbitol polyglycidyl ether, and a combination thereof.

### Claim 17 (depends on 10)

The method of claim 10, wherein the ethanol-containing aqueous alkaline solution contains about 5 to about 13% w/w of ethanol.

### Claim 18 (depends on 10)

The method of claim 10, wherein the ethanol-containing aqueous alkaline solution is an aqueous sodium hydroxide solution of about 0.7 to 1.3% w/w containing about 5 to about 13% w/w of ethanol.
